



NASDAQ Listing Application Update

NEW YORK and SYDNEY, Australia, February 1, 2022 - Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), wishes to advise shareholders that it has filed a further update to its Form F-1/A registration statement ("Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of the Company's ordinary shares on the Nasdaq Capital Market. The Registration Statement has not yet been declared effective by the SEC.

The Company has applied to list its ordinary shares on the Nasdaq Capital Market in the United States under the symbol "BRNI".

Joseph Stone Capital LLC has been appointed the Lead Book Running Manager and Valuable Capital Limited has been appointed as Co-Book Running Manager of the offering.

The number of shares to be offered and sold and the amount to be raised under the proposed U.S public offering have not yet been determined. There can be no assurance that the Company's proposed listing on the Nasdaq Capital Market will be approved or that the initial public offering will be completed.

This press release is being made pursuant to, and in accordance with, Rule 135 under the U.S. Securities act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of that jurisdiction. Furthermore, this press release is being made to comply with National Stock Exchange of Australia ("NSX") listing rules and regulations and will not be disseminated in the United States or outside the Commonwealth of Australia.

-End-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialisation of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC Markets in the USA.

To learn more about Beroni, please visit www.beronigroup.com.
For further information, please contact us at:

Phone: +61 2 9159 1827

Email: enquiry@beronigroup.com

Website: www.beronigroup.com